MRMyungsun Ro

Myungsun Ro

*This is an algorithmically generated author record based on publicly available information.

Myungsun Ro has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Inpatient Use of Continuous Glucose Monitors: Insights From Pennsylvania Patient Safety Event Reports

    by Christine E. Sanchez, Myungsun Ro, Rebecca Jones

    Introduction: Inpatient use of continuous glucose monitors (CGMs) has historically been prohibited. Increased outpatient use, critical needs during the COVID-19 pandemic, and growing interest in allowing use of CGMs to manage blood glucose levels for hospitalized patients have prompted consideration of allowing inpatient use of these devices to manage blood glucose levels. Methods: We conducted a retrospective mixed-methods study using event reports submitted to the Pennsylvania Patient Safety Reporting System (PA-PSRS) from 2022 to 2025 to identify inpatient safety events in which the presence or use of a CGM could have influenced the risk of patient harm. Structured and narrative data were coded and analyzed to characterize variables related to CGM use and assess the potential impact of CGMs on patient safety. Results: We identified and analyzed 165 reports from 51 hospitals. More than 70% of reports described events in which the presence or use of a CGM increased the risk of patient harm (CGM risk events), while the remaining reports described a reduced risk (CGM mitigation events). Among CGM risk events, the most frequent issues were off-policy blood glucose monitoring (23.9%), missing CGM-related documentation (17.1%), malfunctioned and/or expired CGM (15.4%), unauthorized insulin administration (13.7%), and failure to remove or cover CGM (9.4%). Patients’ desire to use their personal CGM appeared across several CGM risk events, whereas transparent communication of glycemic information between patients and providers was commonly described in CGM mitigation events. Conclusion: Data from this study showed that inpatient CGM use was associated with both increased and reduced risk of patient harm. Clear policies and consistent patient-provider communication may help to minimize these risks and enhance patient benefit. Plain Language Summary: Many people with Type 1 or Type 2 diabetes use continuous glucose monitors (CGMs). These small wearable devices help track blood sugar levels throughout the day. Even though people commonly use continuous glucose monitors at home, hospitals have been slower to allow their use. This is due to uncertainty concerning their safety and accuracy in a clinical setting, versus the standard procedure of finger-stick blood testing several times a day. However, recent research, and the Food and Drug Administration’s temporary approval of in-hospital CGM use during the height of the COVID-19 pandemic, suggest that when used correctly, CGMs can be a reliable alternative to finger-stick tests, as well as offer additional benefits in monitoring and maintaining glucose levels of inpatients. A recent review by Patient Safety Authority research scientists discovered that inpatient CGM use can be associated with both an increased and decreased risk of harm. Researchers found that when CGMs increased risk of harm, issues such as off-policy blood glucose monitoring, missing documentation, and unauthorized insulin administration occurred. However, the data representing a decreased risk of harm associated with CGM use highlights the potential for CGMs to be useful tools during a hospital stay. As CGM usage increases due to patient preferences and shifting hospital policies, facilities should consider the strategies outlined in this article and establish clear, consistent procedures and collaborative communication between patients and providers to foster safe, effective CGM use.

  • Open Access

    Large-Scale Insulin Overdoses From Syringe-Related Errors: Analysis and Insights Across 47 Hospitals

    by Myungsun Ro, Rebecca Jones

    Background: Insulin is a high-alert medication associated with numerous medication errors. We sought to analyze syringe-related issues which we defined as the use or selection of a syringe during insulin preparation, dispensing, or administration that contributed to, or had the potential to contribute to, a dosing error or discrepancy. Methods: A retrospective mixed-methods study was conducted using Medication Error event reports from the Pennsylvania Patient Safety Reporting System (PA-PSRS) from 2015 to 2024. A targeted query identified reports involving U-100 insulin and syringe-related issues resulting in dosing errors or near misses. Structured and free-text data were coded for variables such as clinical indication, route of administration, wrong dose ratio, syringe size, and contributing factors. Results: Seventy-four reports across 47 facilities met inclusion criteria. Serious events accounted for over one-third of errors that reached the patient. Tenfold overdoses were most frequent, occurring in 56.4% of reports with a wrong dose ratio, followed by hundredfold overdoses in 20.0%. Reports from the emergency department care area group had the highest frequency of tenfold overdoses, while intensive care unit reports had the greatest proportion of hundredfold overdoses. More than 97% of wrong dose errors that reached the patient resulted in an overdose of tenfold or greater. Among reports specifying syringe volume, 73.8% involved a 1-milliliter syringe; 95.2% of overdoses in these reports were exactly tenfold. Contributing factors included improper syringe storage, similar appearance, and lack of provider experience. Variability in hospital insulin protocols and formularies was also observed. Conclusion: Syringe-related issues present a serious and preventable threat to patient safety. Facilities are encouraged to evaluate their insulin protocols and adopt strategies to prevent and mitigate patient harm associated with syringe-related issues. Plain Language Summary: Although insulin is used daily by millions of people around the world, it is considered a high-alert drug that has been associated with more medication errors than any other medication type or class. One challenge in administering insulin is that it is measured in “units” rather than milliliters (mL), requiring unique insulin syringes with the appropriate markings. Using a syringe intended for other medication to administer insulin could lead to an overdose of up to 100 times the intended dose. To identify contributing factors and develop strategies to reduce the risk of wrong dose errors related to the use or selection of syringes, researchers focused on event reports submitted by Pennsylvania facilities over the last decade that involved U-100 insulin and syringe-related issues resulting in dosing errors or near misses. Some of the key takeaways of their detailed study—which encompassed 74 reports from 47 facilities—are that over a third of errors that reached the patient were serious events and among reports specifying syringe volume, 73.8% involved a 1-mL syringe. Contributing factors included using the wrong syringe due to improper syringe storage, similar cap color or packaging, and provider’s lack of experience. Variability in hospital insulin protocols and formularies was also observed. The authors encourage facilities to evaluate and standardize their existing insulin protocols and formularies, and implement the suggested safety strategies for preventing syringe-related insulin dose errors.


  • Open Access

    Strategies to Prevent Five-Fold Wrong Dose Errors With U-500 Insulin

    by Myungsun Ro

    By Myungsun Ro. PSA has received several reports via the Pennsylvania Patient Safety Reporting System (PA-PSRS) describing errors with U-500 insulin that led to patients receiving either five times less or five times...


  • Open Access

    A Fatal Medication Error Involving Neuromuscular Blocking Agent and Insights From Wrong Drug Events in Pennsylvania

    by Myungsun Ro

    By Myungsun Ro. The Patient Safety Authority (PSA) recently received a report describing a fatal medication error that highlights persistent risks involving wrong drug events.

  • Open Access

    Wrong Drug Events Across Pennsylvania Healthcare Facilities: A Systematic Analysis of Medication Pairs, Class Patterns, and Clinical Safety Implications

    by Myungsun Ro, Rebecca Jones

    Background: Medication errors represent a significant challenge to patient safety. Wrong drug events (WDEs), which occur when a patient receives a medication different from the one intended, can cause serious patient harm. Methods: We queried the Pennsylvania Patient Safety Reporting System (PA-PSRS) database for wrong drug medication error reports submitted in calendar year 2023 to identify WDEs that reached the patient in which one medication was inadvertently ordered, dispensed, or administered in place of another medication that contained a different active ingredient. Results: We identified and analyzed 450 WDE reports from 127 different healthcare facilities. Insulin was the most frequently reported medication class, comprising 10.3% (93 of 900) of all reported medications involved in a WDE, followed by antibacterial for systemic use (n=90), electrolyte solution (n=62), and opioid (n=51). Many WDEs occurred within the same medication class, highlighting their shared stem names. Conclusion: WDEs can cause serious patient harm resulting from omission or delay of a necessary medication, administration of an unintended and/or contraindicated medication, or other deviation due to confusion between two medications. Medications belonging to the same class, as well as those sharing similar names, require heightened attention. Additional research regarding the contributing factors to WDEs could provide a more complete understanding of these events and facilitate further development of evidence-based, targeted prevention strategies. Plain Language Summary: It’s easy to mix up names, like say “sucrose” and “sucralose”—the first is commonly called sugar, and the second is an artificial sweetener better known by its brand name, Splenda. Confusing ingredients while baking is usually a harmless mistake, but if you confuse medications, for example Premarin (used to treat symptoms of menopause) and permethrin (used to treat lice), there could be a serious problem. This type of medication error is considered a wrong drug event (WDE), in which a patient receives a medication different from the one intended. WDEs can result in patient harm from missing or delaying needed medication; administering an unnecessary or contraindicated medication; or administering a medication in other incorrect ways, such as wrong route and dose. One major contributing factor to WDEs is confused drug names, involving those that are similar in how they are spoken or written—known as “look-alike, sound-alike” medications. This can occur with generic names (e.g., azithromycin, clarithromycin, and erythromycin), brand names (e.g., Solu-Cortef and Solu-Medrol), abbreviations (e.g., TPA and TNK), or any combination thereof. In this study, researchers analyzed patient safety event reports from the Pennsylvania Patient Safety Reporting System and identified the individual specific medications, pairs, and classes most frequently involved in WDEs and summarized the serious events that resulted in patient harm. Their work highlights the importance of giving close attention to medications with similar names, particularly those within the same medication class that share the same stem, such as “phrine” as in epinephrine and norepinephrine.


  • Open Access

    Strategies for Mitigating Dofetilide-Induced Ventricular Arrhythmias

    by Myungsun Ro

    By Myungsun Ro. In recent years, the Patient Safety Authority has received several reports of QT prolongation in patients receiving dofetilide. Approximately half of these reports were associated with serious adverse events...

  • Open Access

    Wrong-Route Errors Involving Haloperidol: Beware of Its Unintended Intravenous Administration

    by Myungsun Ro

    By Myungsun Ro. Haloperidol is a butyrophenone antipsychotic that is approved for the treatment of schizophrenia. Only the intramuscular route is approved for parenteral use by the U.S. Food and Drug Administration (FDA)...